Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Summary

The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS). The secondary objectives of the study are to obtain preliminary data on the effectiveness of ASN-002 in the treatment of BCCs in individuals with Basal Cell Nevus Syndrome (BCNS) by 1. evaluating the histological clearance of BCCs in patients with BCNS, and 2. assessing the clinical changes of BCCs after treatment with ASN-002, and 3. assessing the systemic effect of ASN-002 by determining response in non-injected lesions 4. assess the safety and clinical changes after a second cycle of ASN-002 injections

Timeline

Start

2017-12-01

Primary completion

2024-12-31

Completion

2025-03-31

Drugs

Indications